.jpg)
The company had in May announced that the US Food and Drug Administration had issued an import alert on its Waluj facility, which makes injectables and solid dosages.
As fear grips the world, demand for protective gear used by health care professionals and citizens is on a rise. And, supply disruption from China has opened a window of opportunities for Indian medical device makers.
Fresh guidelines issued by the Union home ministry on Wednesday permit industries operating in rural areas to run from April 30 with strict social distancing norms.
Index heavyweights ITC was the top gainer along with RIL and HDFC
Financial shares were among the top Sensex gainers along with auto and pharma shares.
The corporate income tax breaks make up a relatively small part of $80 billion in business giveaways.
To address the supply crunch, CII has suggested leveraging the existing excess capacity in the Indian industry; rolling back import duty hike to look for alternative sources of imports; expanding credit to manufacturing units with quick loan sanctions, and one-time emergency waiver of non-performing asset regulations for three months.
There were apprehensions in the SII about rival Bharat Biotech's 'indigenous' tag, opening up shortcuts for it. One senior person, who was very familiar with the sector, told me, 'The message has gone out from the very top. Somani (V G Somani -- drug controller general of India) has told me "Bharat ka karna hai".' A fascinating excerpt from Abantika Ghosh's Billions Under Lockdown: The Inside Story Of India's Fight Against COVID-19.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.
The Sensex ended 290 points higher at 29,095 mark and the Nifty gained 94 points to close at 8,806 levels.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
The US provides large investment opportunities for Indian companies in software, IT services, gas exploration
Asia to stay flat in 2017. India is better-placed given its low export dependence and it should outperform Asian peers this year says Mixo Das, India strategist for financial major Nomura
Over a year after the deadline to grant Most Favoured Nation (MFN) trading status to India, the Pakistani government on Thursday declined to specify any time limit to meet the long-pending demand from here.
Markets climb higher tracking global cues.
Employees asked to work from home... cancelled travel plans... curtailed meetings... Caution and precaution dominate Corporate India's response to Covid-19.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
India is the second largest buyer of Iranian crude, after China.
People are interested in the strength of India's economy, the country's stability, and the opportunities, says Stuart Tait, regional head of commercial banking, Asia-Pacific at HSBC.
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
IT sector's trading multiples hit post-Lehman lows, providing good entry points.
The rupee recovered from more-than three months low of 63.15 in early trade on dollar selling by banks.
Employees in India were more optimistic about the future of their national economy.
NITI Aayog wants the prime minister's flagship initiative should focus on labour-intensive sectors and policies that impede their growth to get special attention.
The multinational has filed infringement proceedings and is seeking an injunction against the Indian rival at the Delhi High Court, trying to block the Bangalore-based biotechnology firm from launching a generic version of Galvus, also known as vildagliptin.
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
The 30-share Sensex provisionally ended up 112 points at 28,555 and the 50-share Nifty closed 24 points higher at 8,561 after hitting a record high of 8,626.95.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Financials were among the top losers along with Sun Pharma and index heavyweight Reliance Industries
Corporate leaders said a stable government at the Centre will help boost infrastructure spend, address agricultural distress, and encouraging employment.
Just like China wants Trump to lose the US presidential poll, it may want Modi to lose the Lok Sabha polls. So months before the 2024 elections, China may take possession of an important area, say one of the Char Dhams, warns Sanjeev Nayyar.
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
India's IPR framework and enforcement were comparable to those in developed countries
'Unless cash has ceased to be king, the issue is the same in the aviation, telecom and ecommerce sectors: Sustainability,' notes T N Ninan.
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
Bharti Airtel , RCom and Tata Communications ended down between 0.1-1%.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances